Eli Lil­ly, No­var­tis back a $26M round for Cavion’s work on neu­ro­log­i­cal dis­eases

The cor­po­rate ven­ture arms of Eli Lil­ly and No­var­tis are back­ing a $26.1 mil­lion round for Char­lottesville, VA-based Cavion, a start­up fo­cused on a pos­si­ble key me­di­a­tor for neu­ro­log­i­cal dis­eases as well as can­cer.

Their drugs tar­get Cav3, which Cavion’s re­searchers say me­di­ates thal­a­m­o­cor­ti­cal dys­rhyth­mia, cov­er­ing a range of dis­eases such as es­sen­tial tremor, Parkin­son’s dis­ease, neu­ro­path­ic pain, epilep­sy as well as or­phan neu­ro-de­vel­op­men­tal and ge­net­ic dis­or­ders such as An­gel­man Syn­drome and Dravet Syn­drome.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER